Beam Therapeutics Inc (BEAM)

Apr 30, 2025

Sage Therapeutics' Q1 Earnings Miss Mark, Revenue Rise Y/Y - TradingView

Apr 30, 2025

Apr 30, 2025

Next Generation Genome Editing Market Future Business - openPR.com

Apr 30, 2025

Apr 30, 2025

(BEAM) Investment Analysis and Advice - news.stocktradersdaily.com

Apr 30, 2025

Apr 26, 2025

BEAM to Discuss Advances in AATD Therapy at Upcoming Conference Call | BEAM Stock News - GuruFocus

Apr 26, 2025

Apr 26, 2025

Beam Therapeutics to Report Q1 Earnings: What's in the Cards? - MSN

Apr 26, 2025

Apr 24, 2025

Cathie Wood’s ARK Sells Adaptive Biotech, Buys Beam Therapeutics Stock By Investing.com - Investing.com Nigeria

Apr 24, 2025

Apr 24, 2025

Cathie Wood’s ARK Sells Adaptive Biotech, Buys Beam Therapeutics Stock - Investing.com

Apr 24, 2025

Apr 23, 2025

Sickle Cell Disease Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies - The Globe and Mail

Apr 23, 2025

Apr 23, 2025

Prime Editing and CRISPR Market is Expected to Reach $23.49 - openPR.com

Apr 23, 2025

Apr 21, 2025

Wolverine World Wide, Pacira BioSciences And Other Big Stocks Moving Higher On Monday - Benzinga

Apr 21, 2025

Apr 20, 2025

Recent uptick might appease Beam Therapeutics Inc. (NASDAQ:BEAM) institutional owners after losing 29% over the past year - simplywall.st

Apr 20, 2025

Apr 14, 2025

How To Trade (BEAM) - news.stocktradersdaily.com

Apr 14, 2025

Apr 12, 2025

Beam Therapeutics (BEAM) Moves 12.6% Higher: Will This Strength Last? - MSN

Apr 12, 2025

Apr 11, 2025

Beam Therapeutics Inc.'s (NASDAQ:BEAM) recent 11% pullback adds to one-year year losses, institutional owners may take drastic measures - Yahoo Finance

Apr 11, 2025

Apr 10, 2025

Cathie Wood's ARK ETF focuses on Beam Therapeutics, Coinbase stock - Investing.com

Apr 10, 2025

Apr 08, 2025

Biotech Firm Uncovers Gene Therapy Breakthrough in Portugal - streetwisereports.com

Apr 08, 2025

Apr 08, 2025

Share Price Appreciation of Biotech Due Over Next Six Months - streetwisereports.com

Apr 08, 2025

Apr 07, 2025

H.C. Wainwright maintains $80 target on Beam Therapeutics stock By Investing.com - Investing.com India

Apr 07, 2025

Apr 07, 2025

Beam Therapeutics Presents Biomarker Data For BEAM-302 Gene Therapy For Inherited Disease - AOL.com

Apr 07, 2025

Apr 07, 2025

H.C. Wainwright maintains $80 target on Beam Therapeutics stock - Investing.com

Apr 07, 2025

Apr 06, 2025

Beam Therapeutics Presents Additional Data for BEAM-302 in - GlobeNewswire

Apr 06, 2025

Apr 05, 2025

Beam Presents Addl. Data From Phase 1/2 Trial Of BEAM-302 In Alpha-1 Antitrypsin Deficiency - Nasdaq

Apr 05, 2025

Apr 05, 2025

Breakthrough: New BEAM-302 Data Shows 91% Success Rate in Rare Liver Disease Treatment - Stock Titan

Apr 05, 2025

Apr 04, 2025

Cathie Wood Just Made A Bold Move—Why She Spent Over $65M On Tesla, Robinhood, And Coinbase 'As The Market Crashed' - Benzinga

Apr 04, 2025

Apr 04, 2025

Beam Therapeutics executive sells $55,330 in stock By Investing.com - Investing.com South Africa

Apr 04, 2025

Apr 04, 2025

Beam Therapeutics executive sells $55,330 in stock - Investing.com Australia

Apr 04, 2025

Apr 03, 2025

Beam Therapeutics’ chief legal officer sells $104,121 in stock By Investing.com - Investing.com Canada

Apr 03, 2025

Apr 03, 2025

Beam Therapeutics’ chief legal officer sells $104,121 in stock - Investing.com India

Apr 03, 2025

Apr 03, 2025

Beam Therapeutics CEO John Evans sells $562,684 in stock By Investing.com - Investing.com India

Apr 03, 2025

Apr 03, 2025

Beam Therapeutics CEO John Evans sells $562,684 in stock - Investing.com

Apr 03, 2025

Apr 03, 2025

Beam Therapeutics president sells $136,418 in stock - Investing.com

Apr 03, 2025

Apr 03, 2025

Beam Therapeutics Executives Sell Shares for Tax Obligations and Personal Sales - TradingView

Apr 03, 2025

Apr 03, 2025

7 Top Gene-Editing Stocks to Buy | Investing | U.S. News - Money/ US News

Apr 03, 2025

Apr 02, 2025

Gene Editing: CRISPR Therapeutics vs. Beam Therapeutics - Securities.io

Apr 02, 2025

Apr 01, 2025

Beam Therapeutics Becomes Oversold - Nasdaq

Apr 01, 2025

Apr 01, 2025

Is Beam Therapeutics Inc. (BEAM) the Best Gene-Editing Stock to Buy? - Yahoo Finance

Apr 01, 2025

Mar 31, 2025

8 Best Gene-Editing Stocks to Buy - Insider Monkey

Mar 31, 2025

Mar 31, 2025

Biotech stocks plunge as FDA’s Peter Marks resigns over RFK Jr. dispute, Moderna and Beam Therapeutics hit hard - TradingView

Mar 31, 2025

Mar 31, 2025

Beam Therapeutics’ SWOT analysis: base editing pioneer faces gene therapy hurdles - Investing.com Canada

Mar 31, 2025

Mar 31, 2025

Beam Therapeutics’ SWOT analysis: base editing pioneer faces gene therapy hurdles By Investing.com - Investing.com South Africa

Mar 31, 2025

Mar 31, 2025

The Zacks Analyst Blog Highlights Illumina, BEAM, Twist Bioscience, Wave Life Sciences and CRISPR Therapeutics - Yahoo Finance

Mar 31, 2025

Mar 31, 2025

BEAM's IND for BEAM-302 in Genetic Disorder Study Gets FDA Clearance - MSN

Mar 31, 2025

Mar 29, 2025

Beam Therapeutics (BEAM) Upgraded to Buy by Bank of America on P - GuruFocus

Mar 29, 2025

Mar 28, 2025

Beam Therapeutics (BEAM) Upgraded by BofA on Promising Genetic T - GuruFocus

Mar 28, 2025

Mar 28, 2025

B of A Securities Upgrades Beam Therapeutics (BEAM) - MSN

Mar 28, 2025

Mar 28, 2025

Beam upgraded to Buy at BofA Securities on recent genetic condition treatment - Seeking Alpha

Mar 28, 2025

Mar 28, 2025

Beam Therapeutics stock rises after FDA clearance for BEAM-302 IND By Investing.com - Investing.com South Africa

Mar 28, 2025

Mar 28, 2025

Beam Therapeutics stock rises after FDA clearance for BEAM-302 IND - Investing.com

Mar 28, 2025